VERICEL CORPORATION Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax
VERICEL CORPORATION (VCEL) had Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax of $39.00 thousand as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Notes › Debt Securities, Available-for-Sale, Fair Value to Amortized Cost, after Allowance for Credit Loss
us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax · last filed 2026-07-30
- 2026-06-30: Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax $39.00K.
- 2026-03-31: Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax $97.00K.
- 2025-12-31: Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax $315.00K.
- 2025-09-30: Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax $293.00K.
| Period end | Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax |
|---|---|
| 2026-06-30 | $39.00K 10-Q · filed 2026-07-30 |
| 2026-03-31 | $97.00K 10-Q · filed 2026-05-07 |
| 2025-12-31 | $315.00K 10-Q · filed 2026-07-30 |
| 2025-09-30 | $293.00K 10-Q · filed 2025-11-06 |
| 2025-06-30 | $218.00K 10-Q · filed 2025-07-31 |
| 2025-03-31 | $173.00K 10-Q · filed 2025-05-08 |
| 2024-12-31 | $122.00K 10-K · filed 2026-02-26 |
| 2024-09-30 | $375.00K 10-Q · filed 2024-11-07 |
| 2024-06-30 | $5.00K 10-Q · filed 2024-08-01 |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-08 |
| 2023-12-31 | $1.00K 10-K · filed 2025-02-27 |
| 2023-09-30 | $0.00 10-Q · filed 2023-11-08 |
| 2023-06-30 | $0.00 10-Q · filed 2023-08-02 |
| 2023-03-31 | $5.00K 10-Q · filed 2023-05-10 |
| 2022-12-31 | $0.00 10-K · filed 2024-02-29 |
| 2022-09-30 | $0.00 10-Q · filed 2022-11-09 |
| 2022-06-30 | $0.00 10-Q · filed 2022-08-03 |
| 2022-03-31 | $0.00 10-Q · filed 2022-05-04 |
| 2021-12-31 | $0.00 10-K · filed 2023-02-23 |
| 2021-09-30 | $0.00 10-Q · filed 2021-11-09 |
| 2021-06-30 | $0.00 10-Q · filed 2021-08-04 |
| 2021-03-31 | $0.00 10-Q · filed 2021-05-05 |
| 2020-12-31 | $20.00K 10-K · filed 2022-02-24 |
| 2020-09-30 | $78.00K 10-Q · filed 2020-11-05 |
| 2020-06-30 | $145.00K 10-Q · filed 2020-08-05 |
| 2020-03-31 | $106.00K 10-Q · filed 2020-05-11 |
| 2019-12-31 | $21.00K 10-K · filed 2021-02-24 |
| 2019-09-30 | $29.00K 10-Q · filed 2019-11-05 |
| 2019-06-30 | $38.00K 10-Q · filed 2019-08-06 |
| 2019-03-31 | $5.00K 10-Q · filed 2019-05-07 |
| 2018-12-31 | $0.00 10-K · filed 2020-02-25 |
| 2018-09-30 | $0.00 10-Q · filed 2018-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |